Islas DAS, Carrillo GJE, Juárez VA, Rotberg T, Fabregat JR

Language: Spanish
References: 11
Page: 486-492
PDF size: 155.48 Kb.

ABSTRACT

Background: The concentration of BNP rises quickly in the first 24 hours after the acute myocardial infarction. The relationship between this increase and the appearance of arrhythmias is ignored.
Objective: To demonstrate that the high concentration of BNP is translated in more bias to mortal and bad presaged arrhythmias.
Results: A prospective study with 60 patients divided in 2 groups those who presented arrhythmias 41 subjects 68.33% and those who did not present arrhythmias patient 19 31.66 %. NYHA I [n (%)]: 18 (94) vs 12 (29.3), p ‹ 0.001; NYHA the II: 1 (5.3) vs 15 (36.6), p = 0.011; NYHA the III: 0 (0) vs 13 (31.7), p = 0.003; low risk unstable angina: 8 (42.1) vs 4 (9.8), p = 0.006; previous AMI: 0 (0) vs 8 (19.5), p = 0.037; troponin I › 0.5: 26.3 vs 34 (82.9), p ‹ 0.001; FEVI ‹ 40%: 0 (0) vs 23 (63.4), p ‹ 0.001, duration of the chest pain (min.), Md (25&#deg;-75&#deg;): 120 (30-240) vs 240 (120-720), p = 0.003; treatment for ICC: 0 (0) vs 8 (19.5), p = 0.039; BNP (pg/mL), Md (25&#deg;-75&#deg;): 49 (41-66) vs 444 (196-894), p ‹ 0.001.
Conclusions: The concentration of BNP in patients with acute coronary syndrome provides information about the heart suffering for isquemia or stress of the wall. That allows to infer acute complications of arrhythmic type in the acute phase, since a relationship exists between the high concentrations of BNP and the appearance of arrhythmias of bad presage.

REFERENCES

1. Burnett JC, Granger JP, Opgenorth TJ. Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol 1984;247:F863-6.

2. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37:1221-7.

3. Kohno M, Yokokawa K, Horio T, Yasunari K, et al. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res 1992;70:241-7.

4. Kohno M, Yasunari K, Yokokawa K, Murakawa K, et al. Inhibition by atrial and brain natriuretic peptides of endothelin-1 secretion after stimulation with angiotensin II and thrombin of cultured human endothelial cells. J Clin Invest 1991;87:1999-2004.

5. Horio T, Kohno M, Takeda T. Effects of arginine vasopressin, angiotensin II and endothelin-1 on the release of brain natriuretic peptide in vivo and in vitro. Clin Exp Pharmacol Physiol 1992;19:575-82.

6. Lainchbury JG, Burnett JC, Meyer DM, Redfield MM. Effects of the natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circul Physiol 2000;278:H33-40.

7. Suhasini M, Li H, Lohmann SM, Boss GR, Pilz RB. Cyclic-GMPdependent protein kinase inhibits the Ras/Mitogen-activated protein kinase pathway. Mol Cell Biol 1998;18:6983-94.

8. D’Souza SP, Yellon DM, Martin C, Schulz R, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003;284:H1592-600.

9. Uusimaa P, Ruskoaho H, Vuolteenaho O, Niemela M, et al. Plasma vasoactive peptides after acute myocardial infarction in relation to left ventricular dysfunction. Int J Cardiol 1999; 69:5-14.

10. González-Hermosillo JA, Colín L, Iturralde P, Romero L. Un S Islas DA y col. enfoque racional del manejo de las arritmias. Arch Inst Nal Cardiol Mex 1990;60:461-6.

11. Jarcho J, Seidman C. Molecular studies of the atrial natriuretic peptide gene. In: Brenner B, Stein J, editors. Atrial natriuretic peptides. New York: Churchill Livingstone Inc., 1989;pp:1-24.